Tiziana Life Sciences (Tiziana Life Sciences) ROCE % : -103.47% (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tiziana Life Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tiziana Life Sciences's annualized ROCE % for the quarter that ended in Jun. 2023 was -103.47%.

Tiziana Life Sciences ROCE % Historical Data

The historical data trend for Tiziana Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tiziana Life Sciences ROCE % Chart

Tiziana Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-97.06

-50.95

-50.38

Tiziana Life Sciences Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															-60.71	-41.92	-25.38	-87.61	-103.47

Tiziana Life Sciences ROCE % Calculation

Tiziana Life Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-15.39	/	( ( (48.826 - 7.546)	+	(26.477 - 6.663) )	/ 2 )
	=	-15.39	/	( (41.28	+	19.814)	/ 2 )
	=	-15.39	/	30.547
	=	-50.38 %

Tiziana Life Sciences's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-17.224	/	( ( (26.477 - 6.663)	+	(17.418 - 3.94) )	/ 2 )
	=	-17.224	/	( ( 19.814	+	13.478 )	/ 2 )
	=	-17.224	/	16.646
	=	-103.47 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Tiziana Life Sciences (NAS:TLSA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tiziana Life Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Tiziana Life Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tiziana Life Sciences (Tiziana Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tiziana Life Sciences Ltd (NAS:TLSA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0RP:Germany

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM 11

Website

https://www.tizianalifesciences.com

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.